Cordis to distribute Ostial Pro stent positioning system worldwide
3 Dec 2010
Cordis Corporation has entered into a distribution agreement
with Ostial Solutions for the worldwide distribution of the Ostial Pro
Stent Positioning System.
The Ostial Pro is an aorto-ostial stent positioning system for
coronary and peripheral applications. It is intended to optimize the
treatment of patients who require a stent implantation for treatment
for aorto-ostial blockages.
“Ostial Pro is a simple solution to a principal challenge of
aorto-ostial stent positioning by providing visual and tactile
identification of the true ostium”
Aorto-ostial blockages occur at the origin of blood vessels
arising from the aorta. This occurs in the right and left main
coronary (heart) arteries, in coronary bypass grafts and in the
renal (kidney) arteries. These aorto-ostial blockages comprise
approximately 95% of all renal stent interventions and 8% of
coronary stent interventions. The worldwide market for aorto-ostial
stent procedures is estimated to be approximately 300,000 cases per
year.
It is critical for the end of the stent to be positioned so as to
align precisely with the origin of the blood vessel in these cases.
Using two-dimensional x-ray imaging and angiography to accomplish
this is challenging, time consuming, and can lead to increased cost
and length of procedures, as well as increased exposure of patients
to radiation and x-ray dye.
Imprecise positioning of aorto-ostial stents often requires the
use of additional stents to treat the lesion, and may increase risks
of renarrowing, or hinder the re-entrance to the blood vessel should
future intervention be needed.
“Ostial Pro is a simple solution to a principal challenge of
aorto-ostial stent positioning by providing visual and tactile
identification of the true ostium,” said Campbell Rogers, MD Chief
Scientific Officer and Global Head Research and Development, Cordis
Corporation.
“The Ostial Pro facilitates precise stent implantation of
aorto-ostial stents by identifying the true ostium. This can help
make precise stent placement easier, safer, and more predictable.
This technology may reduce the need for additional stents and may
reduce the risk of having to perform another intervention for
restenosis. Based on these benefits, this simple device should
become a standard element of aorto-ostial stenting.”
The Ostial Pro is currently FDA cleared, and is currently being
sold only in the United States by Ostial Solutions. Cordis plans to
assume worldwide distribution of the Ostial Pro in the first half of
2011.